CAR T Cells Reset Autoimmunity While AI Erases Its Own Teachers

A 49-year-old nurse gave up carrying her grandchildren because she was afraid she'd fall. That detail alone captures what autoimmune disease actually takes from people — not just health, but the texture of ordinary life.

Jan Janisch-Hanzlik has multiple sclerosis. The best available medications weren't slowing her decline, and she was already eyeing a future in a wheelchair. So when she heard about a clinical trial testing CAR T cell therapy for MS at the University of Nebraska Medical Center, she did something that tells you everything about how desperate autoimmune patients have become: she called the clinic every other month until they let her in.

CAR T — chimeric antigen receptor T cell therapy — was originally engineered to fight cancer. The basic idea is elegant and a little wild. Scientists extract a patient's own T cells, the immune system's frontline hunters, and reprogram them in a lab to recognize and destroy a specific target. Then they infuse those modified cells back into the patient, essentially deploying a custom-built biological weapon.

It works. The FDA approved the first CAR T therapy for an aggressive leukemia back in 2017, and since then it has produced long-term remission in patients who had almost no other options. For blood cancers in particular, the results have been stunning enough to make oncologists genuinely emotional at conferences.

Now researchers are asking a logical follow-up question: if CAR T can hunt down malignant cells, can it also hunt down the misbehaving immune cells responsible for autoimmune diseases? In conditions like lupus, MS, Graves' disease, and vasculitis, the immune system essentially turns on the body itself. The theory is that wiping out those rogue cells could reset the immune system to something resembling its pre-disease state — a hard reboot, biologically speaking.

Hundreds of clinical trials are now testing this across a range of autoimmune conditions. Early results in some lupus patients have been striking enough to generate serious excitement in immunology circles. But the field is still early, and the honest answer to most of the big questions is: we don't know yet.

How durable are the benefits? Could the disease come back once the CAR T cells fade? What are the long-term side effects of essentially wiping out a major branch of your immune system? These aren't rhetorical concerns — CAR T carries real risks, including a dangerous inflammatory response called cytokine release syndrome that requires close monitoring.

Janisch-Hanzlik received her infusion on June 9, 2025, knowing all of this. She spent the following week being watched for exactly those complications. Her motivation, beyond her own suffering, was pointed: MS has a genetic component, and her two young grandchildren carry elevated risk. She wanted to be able to tell them she tried everything.

That combination — a proven cancer technology, a massive unmet medical need, and patients willing to take real risks for a chance at remission — is what makes this moment in autoimmune research feel genuinely different. Whether CAR T delivers on that promise is still an open question. But the question itself is now being asked in operating rooms, not just laboratories.